When the SIL controls were compared with cervical cancer cases, it was found that CCR2-64I carriers are at more risk of developing cervical cancer (P = 0.001, OR (95% CI) = 6.86 (4.19-11.21)) from SIL. This evidence concerns the gene CCR2 and cervical cancer.